Compare KALA & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALA | ABSI |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 357.9M |
| IPO Year | 2017 | 2021 |
| Metric | KALA | ABSI |
|---|---|---|
| Price | $0.17 | $3.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $31.50 | $6.96 |
| AVG Volume (30 Days) | 2.7M | ★ 4.1M |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 67.39 | 10.64 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | N/A | $215.96 |
| Revenue Next Year | N/A | $319.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $2.24 |
| 52 Week High | $20.58 | $5.23 |
| Indicator | KALA | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 34.98 | 67.75 |
| Support Level | $0.15 | $2.48 |
| Resistance Level | $0.24 | $4.11 |
| Average True Range (ATR) | 0.02 | 0.27 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 15.73 | 75.56 |
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.